Active substanceGlucosamine + chondroitin sulfateGlucosamine + chondroitin sulfate
Similar drugsTo uncover
  • ARTRA®
    pills inwards 
    Unipharm, Inc.     USA
  • Arthravir®-complex-INCAMFARM®
    capsules inwards 
    TRIVIUM-XXI, LLC     Russia
  • KONDRONOVO®
    capsules inwards 
  • Structum®
    capsules inwards 
  • Tazan®
    pills inwards 
    MS-VITA, LLC     Russia
  • Tazan®
    pills inwards 
    MS-VITA, LLC     Russia
  • Teraflex®
    capsules inwards 
    BAYER, AO     Russia
  • Chondroglucose
    gel externally 
    SYNTHESIS, OJSC     Russia
  • Chondroglucose
    pills inwards 
    MS-VITA, LLC     Russia
  • Hondroflex
    capsules inwards 
  • Dosage form: & nbspFilm-coated tablets.
    Composition:

    For 1 tablet:

    Active substances:

    Glucosamine Sodium Chloride Sulfate

    314 mg

    (in terms of glucosamine sulfate)

    250 mg

    Chondroitin sodium sulfate

    250 mg

    Excipients:

    Silica colloidal dioxide (aerosil)

    4.25 mg

    Calcium stearate

    8.5 mg

    Talc

    25.5 mg

    Crospovidone (callidone CML, kollidone CL-M)

    85.0 mg

    Povidone low molecular weight (polyvinylpyrrolidone low molecular weight medical 12600 + 2700)

    43.0 mg

    Potato starch

    2.25 mg

    Ludipress (composition: lactose monohydrate - 91-95%, povidone - 3-4%, crospovidone - 3-4%)

    117.5 mg

    Shell composition:

    Hypromellose (hydroxypropylmethylcellulose)

    13.6 mg

    Propylene glycol

    1.25 mg

    Macrogol (polyethylene glycol 4000)

    11.9 mg

    Titanium dioxide

    8.25 mg

    Description:Biconvex tablets are oval, covered with a film membrane from white to almost white. Roughness of the surface of tablets is allowed.
    Pharmacotherapeutic group:tissue repair stimulant
    ATX: & nbsp

    M.01.A.X   Other non-steroidal anti-inflammatory drugs

    Pharmacodynamics:

    Stimulates the regeneration of cartilaginous tissue. Glucosamine and chondroitin sulfate are involved in the synthesis of connective tissue, helping to prevent cartilage destruction processes and stimulating tissue regeneration. The introduction of exogenous glucosamine enhances the production of the cartilaginous matrix and provides non-specific protection against chemical damage to the cartilage.

    Glucosamine in the form of a sulfate salt is a precursor of hexosamine, and the sulfate anion is necessary for the synthesis of glycosaminoglycans. Another possible function of glucosamine is to protect the damaged cartilage from metabolic destruction caused by non-steroidal anti-inflammatory drugs and glucocorticosteroid, as well as its own moderate anti-inflammatory effect.

    Chondroitin sulfate regardless of whether it is absorbed in an intact form or as separate components, serves as an additional substrate for the formation of a healthy cartilage matrix. Stimulates the formation of hyaluronone, the synthesis of proteoglycans and collagen type II, and also protects hyaluronone from enzymatic cleavage (by suppressing the activity of hyaluronidase) and the damaging effect of free radicals; maintains the viscosity of the synovial fluid, stimulates mechanisms of cartilage repair. In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for non-steroidal anti-inflammatory drugs.

    Pharmacokinetics:

    Glucosamine: bioavailability with oral intake - 25% (effect of "first passage" through the liver). Distributed in tissues: the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue. It is excreted mainly by the kidneys in unchanged form; partially - the intestine. Half-life is 68 h.

    Chondroitin sulfate: when taken orally once in a dose of 0.8 g (or 2 times a day at a dose of 0.4 g), the concentration in the plasma increases for 24 hours. Absolute bioavailability - 12%.About 10 and 20% of the dose received is absorbed in the form of high molecular weight and low molecular weight derivatives, respectively. The apparent volume of distribution is about 0.44 ml / g. It is metabolized by desulfurization. It is excreted by the kidneys. The half-life is 310 min.

    Indications:Osteoarthritis I-III Art.
    Contraindications:

    Hypersensitivity to the components of the drug, children under 15 years, severe renal dysfunction, pregnancy and the period of breastfeeding.

    Carefully:Bleeding, a tendency to bleeding, diabetes, bronchial asthma.
    Pregnancy and lactation:

    During pregnancy and during breastfeeding (lactation) the drug is contraindicated.

    Dosing and Administration:

    Inside.

    Adults and children over 15 years of age: 2 tablets 2 times a day for the first three weeks; 2 tablets 1 time per day for the following weeks and months.

    Steady therapeutic effect is achieved when taking the drug for at least 6 months.

    Side effects:

    Classification of the alleged frequency of side effects: often - 1/100 of prescriptions (1-10%), very rarely - less than 1/10000 prescriptions (less than 0.01%, including individual cases).

    Often - Dysfunction of the gastrointestinal tract (epigastric pain, flatulence, diarrhea or constipation), dizziness, skin allergic reactions, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia.

    Rarely - Allergic reactions.

    Overdose:

    Symptoms: cases of overdose are unknown.

    Treatment: gastric lavage, symptomatic therapy.

    Interaction:

    Increases absorption tetracyclines, reduces the effect semisynthetic penicillins and glucosamine.

    A drug compatible with non-steroidal anti-inflammatory drugs and glucocorticosteroid.

    maybe intensification of action anticoagulants, antiplatelet agents, fibrinolytic agents.

    Special instructions:

    If there are undesirable effects from the gastrointestinal tract, the dose of the drug should be reduced 2 times, and in the absence of improvement - cancel the drug.

    If there is no clinical effect after the treatment course of 8 tablets per day for 4 weeks, the question of clarifying the diagnosis should be solved.

    Effect on the ability to drive transp. cf. and fur:

    Care must be taken when driving vehicles and practicing other potentiallydangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    The tablets covered with a film membrane, 250 mg + 250 mg.

    Packaging:

    5, 15 tablets per contour cell package.

    For 30, 60 or 90 tablets in cans of polymeric.

    Each can, 6, 12 or 18 contour cell packs of 5 tablets or 2, 4 or 6 contiguous cell packs of 15 tablets with instructions for medical use are placed in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003620
    Date of registration:12.05.2016
    Expiration Date:12.05.2021
    The owner of the registration certificate:MS-VITA, LLC MS-VITA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia
    Information update date: & nbsp10.07.2016
    Illustrated instructions
      Instructions
      Up